Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

The idea of creating a gray zone in the payer message is to take the onus off of having to heavily discount for equal access ...

Founder and CEO of Alume Biosciences, Quyen Nguyen, MD, PhD, discusses nerve regeneration, nerve visualization and the reason behind what she does at Alume Biosciences.

With this is mind, Abbott announced a new program that combines one of the most popular sports in the world with education ...

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such ...

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving ...

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...